Wei Gou
Yuquan Road 19
Yuquan, 100049, China
Yuquan, 100049, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Potential-gradient reprogramming of zinc-based membranes for orthopedic applications.
Journal: Acta biomaterialia
Published: March 12, 2026
Efficacy and Safety of Firsekibart in Patients with Acute Gout Unsuitable for Standard Therapy: 48-Week Results from an Open-Label Extension of a Randomized Phase 3 Trial.
Journal: Advances in therapy
Published: February 13, 2026
SSGJ-613 Alleviates Pain and Reduces the Risk of Acute Flares in Patients With Gout: A Randomized, Double-Blind, Phase II Study.
Journal: International journal of rheumatic diseases
Published: December 30, 2025
Xeligekimab, an Interleukin-17A Antagonist for Active Radiographic Axial Spondyloarthritis in Chinese Patients: 16- and 48-Week Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study.
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: October 28, 2025
Evaluation of the Safety, Tolerability, Pharmacokinetics, and Efficacy of Subcutaneous Firsekibart in Gout: A Phase Ib/II Clinical Trial.
Journal: International journal of rheumatic diseases
Published: October 17, 2025
Evolution of calyx diversity in angiosperms: a focus on transcriptomic repatterning mechanisms underlying inflated fruiting calyx within Solanaceae.
Journal: The Plant journal : for cell and molecular biology
Published: September 09, 2025
A randomized, double-blind, placebo-controlled and dose-ranging study to evaluate the safety and efficacy of XG005 in subjects with painful osteoarthritis of the knee.
Journal: Osteoarthritis and cartilage open
Published: July 01, 2025
Efficacy and Safety of Firsekibart Compared to Etoricoxib for Gout Flares: A Phase 2, Multicenter, Open-label, Active-controlled, Randomized Non-inferiority Trial.
Journal: Rheumatology and therapy
Published: June 30, 2025
Firsekibart as a Prophylactic Treatment for Acute Gout Flare in Participants Initiating Urate-Lowering Therapy: A Phase 2, Randomized, Open-Label, Multicenter, Active-Controlled Trial.
Journal: ACR open rheumatology
Published: April 22, 2025
Firsekibart versus compound betamethasone in acute gout patients unsuitable for standard therapy: A randomized phase 3 trial.
Journal: Innovation (Cambridge (Mass.))
Published: April 20, 2025
Firsekibart in acute gouty arthritis.
Journal: Journal of translational medicine
Published: January 03, 2025
Last Updated: 09/26/2026